Loading...
Nilotinib impairs skeletal myogenesis by increasing myoblast proliferation
BACKGROUND: Tyrosine kinase inhibitors (TKIs) are effective therapies with demonstrated antineoplastic activity. Nilotinib is a second-generation FDA-approved TKI designed to overcome Imatinib resistance and intolerance in patients with chronic myelogenous leukemia (CML). Interestingly, TKIs have al...
Na minha lista:
| Udgivet i: | Skelet Muscle |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5819301/ https://ncbi.nlm.nih.gov/pubmed/29463296 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13395-018-0150-5 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|